Luteolin Induces GPX4-dependent Ferroptosis and Enhances Immune Activation in Colon Cancer.
[BACKGROUND] Ferroptosis is pivotal in colon cancer progression and immunity.
APA
Cao Q, Ding S, et al. (2025). Luteolin Induces GPX4-dependent Ferroptosis and Enhances Immune Activation in Colon Cancer.. Phytomedicine : international journal of phytotherapy and phytopharmacology, 146, 157117. https://doi.org/10.1016/j.phymed.2025.157117
MLA
Cao Q, et al.. "Luteolin Induces GPX4-dependent Ferroptosis and Enhances Immune Activation in Colon Cancer.." Phytomedicine : international journal of phytotherapy and phytopharmacology, vol. 146, 2025, pp. 157117.
PMID
40812220
Abstract
[BACKGROUND] Ferroptosis is pivotal in colon cancer progression and immunity. While the natural flavonoid luteolin has anticancer properties, its ferroptosis targets and immunomodulatory effects in colon cancer are unclear.
[PURPOSE] This study aims to validate luteolin's anticancer efficacy in colon cancer and elucidate its mechanism involving ferroptosis induction and antitumor immune activation.
[METHODS] Integrated WGCNA, machine learning, and functional enrichment techniques to analyze luteolin's potential targets. Comprehensive assays including CCK-8, colony formation, flow cytometry, western blotting, and reactive oxygen species (ROS)/malondialdehyde (MDA)/glutathione (GSH) /FerroOrange profiling, combined with MC38 syngeneic models, were used to investigate luteolin's antiproliferative effects, glutathione peroxidase 4 (GPX4) - dependent ferroptosis induction, and modulation of tumor-infiltrating immune cells. Molecular docking, Cellular Thermal Shift Assay (CETSA), Drug Affinity Responsive Target Stability (DARTS), and surface plasmon resonance (SPR) validated GPX4-luteolin interactions. Anti-CD8 antibody and clodronate liposomes (CLD) immune depletion studies demonstrate that CD8⁺ T cells and macrophages play pivotal roles in activating antitumor immunity.
[RESULTS] Bioinformatics indicated luteolin modulates oxidative stress signaling. Luteolin dose-dependently inhibited colon cancer cell proliferation, reversed by ferroptosis inhibitor Ferrostatin-1. Luteolin triggered ROS/Fe accumulation, lipid peroxidation, MDA elevation, GSH depletion, and GPX4 downregulation. GPX4 overexpression conferred ferroptosis resistance, reversed by luteolin. Besides, luteolin directly bound GPX4, enhancing its thermal stability and suppressing pronase E-mediated degradation. In vivo, luteolin exhibited antitumor efficacy through GPX4 downregulation and ferroptosis induction, synergistically promoting intratumoral M1 macrophage polarization and CD8 T lymphocyte activation.
[CONCLUSION] Luteolin induces ferroptosis by directly targeting GPX4, and promotes antitumor immune responses. These findings reveal a novel mechanism underlying luteolin-induced ferroptosis and provide theoretical support for its immunotherapeutic application in colon cancer.
[PURPOSE] This study aims to validate luteolin's anticancer efficacy in colon cancer and elucidate its mechanism involving ferroptosis induction and antitumor immune activation.
[METHODS] Integrated WGCNA, machine learning, and functional enrichment techniques to analyze luteolin's potential targets. Comprehensive assays including CCK-8, colony formation, flow cytometry, western blotting, and reactive oxygen species (ROS)/malondialdehyde (MDA)/glutathione (GSH) /FerroOrange profiling, combined with MC38 syngeneic models, were used to investigate luteolin's antiproliferative effects, glutathione peroxidase 4 (GPX4) - dependent ferroptosis induction, and modulation of tumor-infiltrating immune cells. Molecular docking, Cellular Thermal Shift Assay (CETSA), Drug Affinity Responsive Target Stability (DARTS), and surface plasmon resonance (SPR) validated GPX4-luteolin interactions. Anti-CD8 antibody and clodronate liposomes (CLD) immune depletion studies demonstrate that CD8⁺ T cells and macrophages play pivotal roles in activating antitumor immunity.
[RESULTS] Bioinformatics indicated luteolin modulates oxidative stress signaling. Luteolin dose-dependently inhibited colon cancer cell proliferation, reversed by ferroptosis inhibitor Ferrostatin-1. Luteolin triggered ROS/Fe accumulation, lipid peroxidation, MDA elevation, GSH depletion, and GPX4 downregulation. GPX4 overexpression conferred ferroptosis resistance, reversed by luteolin. Besides, luteolin directly bound GPX4, enhancing its thermal stability and suppressing pronase E-mediated degradation. In vivo, luteolin exhibited antitumor efficacy through GPX4 downregulation and ferroptosis induction, synergistically promoting intratumoral M1 macrophage polarization and CD8 T lymphocyte activation.
[CONCLUSION] Luteolin induces ferroptosis by directly targeting GPX4, and promotes antitumor immune responses. These findings reveal a novel mechanism underlying luteolin-induced ferroptosis and provide theoretical support for its immunotherapeutic application in colon cancer.
MeSH Terms
Luteolin; Ferroptosis; Colonic Neoplasms; Phospholipid Hydroperoxide Glutathione Peroxidase; Animals; Mice; Humans; Cell Line, Tumor; Reactive Oxygen Species; Molecular Docking Simulation; CD8-Positive T-Lymphocytes; Cell Proliferation; Mice, Inbred BALB C; Antineoplastic Agents, Phytogenic
같은 제1저자의 인용 많은 논문 (5)
- The oral bacterial microbiota change in oral squamous cell carcinoma: a systematic review and meta-analysis.
- Dynamic and extensive A-to-I RNA recoding in immunoglobulin shapes myeloid neoplasm transcriptome.
- Multiparametric MRI to Predict Response to Irreversible Electroporation Plus Anti-PD-1 Immunotherapy in Pancreatic Ductal Adenocarcinoma.
- A Shikonin Derivative Induces Excessive Autophagy in Pancreatic Cancer Cells.
- Defining gastric cancer ecology: the crucial roles of TREM2 macrophages and fibroblasts in tumor microenvironments.